Novo Nordisk appoints Anne Phillips as VP
This article was originally published in Scrip
Novo Nordisk has appointed Dr Anne Phillips as vice-president of clinical development, medical and regulatory affairs for North America. She replaces Dr Per Falk, who was promoted to senior vice-president for Novo Nordisk's biopharmaceuticals research unit in Denmark. Dr Phillips joins from GlaxoSmithKline, where she had worked within the company's R&D organisation since 1998, most recently as vice-president, medicine development leader within GSK's oncology R&D organisation. Dr Phillips will report directly to Jerzy Gruhn, president of the company's US affiliate, and senior vice-president for Novo Nordisk North America, and will serve as a member of the US executive team.